| All (n = 522) | Alive (n = 334) | Dead (n = 188) | Poverall |
---|---|---|---|---|
Age, years | Â | Â | Â | 0.678 |
 > 65, n (%) | 262 (50.2%) | 163 (48.8%) | 99 (52.7%) |  |
 ≤ 65, n (%) | 241 (46.2%) | 159 (47.6%) | 82 (43.6%) |  |
 Unknown, n (%) | 19 (3.64%) | 12 (3.59%) | 7 (3.72%) |  |
Gender | Â | Â | Â | 0.668 |
 Female, n (%) | 280 (53.6%) | 182 (54.5%) | 98 (52.1%) |  |
 Male, n (%) | 242 (46.4%) | 152 (45.5%) | 90 (47.9%) |  |
Stage | Â | Â | Â | < 0.001 |
 Stages I–II, n (%) | 403 (77.2%) | 280 (83.8%) | 123 (65.4%) |  |
 Stages III–IV, n (%) | 111 (21.3%) | 48 (14.4%) | 63 (33.5%) |  |
 Unknown, n (%) | 8 (1.53%) | 6 (1.80%) | 2 (1.06%) |  |
T | Â | Â | Â | 0.005 |
 T1–2, n (%) | 453 (86.8%) | 301 (90.1%) | 152 (80.9%) |  |
 T3–4, n (%) | 66 (12.6%) | 32 (9.58%) | 34 (18.1%) |  |
 Unknown, n (%) | 3 (0.57%) | 1 (0.30%) | 2 (1.06%) |  |
N | Â | Â | Â | < 0.001 |
 N0, n (%) | 335 (64.2%) | 245 (73.4%) | 90 (47.9%) |  |
 N1-3, n (%) | 175 (33.5%) | 81 (24.3%) | 94 (50.0%) |  |
 Unknown, n (%) | 12 (2.30%) | 8 (2.40%) | 4 (2.13%) |  |
M | Â | Â | Â | 0.003 |
 M0, n (%) | 353 (67.6%) | 219 (65.6%) | 134 (71.3%) |  |
 M1, n (%) | 25 (4.79%) | 10 (2.99%) | 15 (7.98%) |  |
 Unknown, n (%) | 144 (27.6%) | 105 (31.4%) | 39 (20.7%) |  |